The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984–2008

  title={The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984–2008},
  author={Patrick J. Murphy},
  journal={Drug Metabolism and Disposition},
  pages={1977 - 1982}
  • P. Murphy
  • Published 1 October 2008
  • Biology
  • Drug Metabolism and Disposition
The dramatic changes in drug metabolism research in the last 25 years are well documented in the publications of the American Society for Pharmacology and Experimental Therapeutics (ASPET). New analytical tools combined with modern molecular biological techniques have provided unprecedented access to the workings of the cell. A field that concentrated on only a handful of primary enzymes now has a list of hundreds in its purview. Genetic variation, environmental impact, and molecular diversity… 

A Personal and Historical Perspective on Drug Metabolism

Significant historical development of drug metabolism is highlighted that shaped the current research and best practices in pharmaceutical companies and the authors recount their personal experiences, spanning over 50 years, which are the base of their perspectives on the utility and future value ofdrug metabolism.

ADME-enabling technologies in drug design and development

ADME-Enabling Technologies in Drug Design and Development focuses on the current state of the art in the field, presenting a comprehensive review of the latest tools for generating ADME data in drug

Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes

Four major BBR metabolites (M1-M4) were identified after phase-I transformation in rat liver, and cell-free reactions showed that CYP2D6, CYP1A2 and CYP3A4 seemed to be the dominant CYP450 isoenzymes transforming BBR into its metabolites M2 and M3.



The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 1, 1909–1958

  • P. Murphy
  • Biology
    Drug Metabolism and Disposition
  • 2008
The period from 1909 to 1958 saw extensive development of the methods required for modern metabolism studies, and examples of trends and specific discoveries are drawn from the archives of ASPET publications.

Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

The current evidence base for pharmacogenetics in relation to drug-metabolizing enzymes is summarized and no other drugs have an evidence base that is sufficient to justify prospective testing at present, although some warrant further evaluation.

Probing the world of cytochrome P450 enzymes.

  • R. Frye
  • Biology
    Molecular interventions
  • 2004
The use of probe drugs alone or in combination can provide an invaluable tool to explore the clinical relevance of genetic and nongenetic factors that affect CYP enzyme activity and thereby contribute substantially to variability in response to therapeutic drugs.

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.

This paper serves to provide one pragmatic approach to addressing the issue of bioactivation from an industry viewpoint based on protocols adopted by Merck Research Laboratories.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to defined a data package that can be expected by regulatory agencies in compound registration dossiers.

Induction of Drug Metabolism: The Role of Nuclear Receptors

In this review, recent findings regarding xenosensors and their target genes are summarized and are put into an evolutionary perspective in regard to how a living organism has derived a system that is able to deal with potentially toxic compounds it has not encountered before.

Human sulfotransferases and their role in chemical metabolism.

Interindividual variation in sulfonation capacity may be important in determining an individual's response to xenobiotics, and recent studies have begun to suggest roles for SULT polymorphism in disease susceptibility.

Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

Reevaluated various approaches used to identify P450 isoform(s) responsible for the metabolism of therapeutic agents and found that in well conducted in vitro experiments, isoform-selective chemical inhibitors can also provide valuable and reliable information.


The background and early history of research leading to the present knowledge of the cytochromes P450 is described, including some of the early events associated with the establishment of the biological function of P450s.